Ajanta Pharma launches of anti-dementia drug memantine HCl in US
The company has launched the drug, which is a generic version of Forest Laboratories' Namenda tablet, in two strengths - 5 mg & 10 mg tablets
 "Ajanta Pharma's Dahej plant in Gujarat")
Ajanta Pharma Ltd, through its wholly owned subsidiary Ajanta Pharma USA Inc, has launched anti-dementia drug, memantine hydrochloride tablet, in the US market. Memantine hydrochloride is a bioequivalent generic version of Forest Laboratories Inc’s Namenda. Ajanta Pharma has launched the drug in two strengths – 5 mg & 10 mg tablets - to address different levels of treatment.
Memantine hydrochloride tablet is part of an ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US Food & Drug Administration (U.S FDA) has granted Ajanta Pharma 10 final approvals and 2 tentative approvals for its abbreviated new drug application (ANDA). Additional 14 ANDAs are pending approval from the FDA.
Memantine hydrochloride tablet is part of an ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US Food & Drug Administration (U.S FDA) has granted Ajanta Pharma 10 final approvals and 2 tentative approvals for its abbreviated new drug application (ANDA). Additional 14 ANDAs are pending approval from the FDA.
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jun 15 2016 | 10:00 AM IST